UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
10.64
-0.07 (-0.65%)
Dec 20, 2024, 4:00 PM EST - Market closed
UroGen Pharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for UroGen Pharma stock have an average target of 44.5, with a low estimate of 25 and a high estimate of 64. The average target predicts an increase of 318.23% from the current stock price of 10.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +134.96% | Dec 6, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +134.96% | Nov 6, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +134.96% | Oct 29, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +134.96% | Oct 21, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +134.96% | Oct 16, 2024 |
Financial Forecast
Revenue This Year
93.79M
from 82.71M
Increased by 13.39%
Revenue Next Year
136.05M
from 93.79M
Increased by 45.06%
EPS This Year
-3.15
from -3.55
EPS Next Year
-2.72
from -3.15
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 98.1M | 159.7M | 411.1M | |||
| Avg | 93.8M | 136.1M | 280.6M | |||
| Low | 89.3M | 111.9M | 215.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 18.6% | 70.3% | 202.1% | |||
| Avg | 13.4% | 45.1% | 106.2% | |||
| Low | 8.0% | 19.3% | 58.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.10 | -1.11 | 2.14 | |||
| Avg | -3.15 | -2.72 | -0.48 | |||
| Low | -3.22 | -4.32 | -1.70 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.